Among the molecular subtypes, patients with HER2-positive BC accounted for 28.0% (n = 21), patients with luminal/HER2-negative BC accounted for 29.3% (n = 22), patients with luminal/HER2-positive BC accounted for 18.7% (n = 14), and patients with TNBC accounted for 24.0% (n = 18). This evidence concerns the gene ERBB2 and breast cancer.